CN111936130A - 包含锶和甲基磺酰基甲烷（msm）的局部制剂及治疗方法 - Google Patents
包含锶和甲基磺酰基甲烷（msm）的局部制剂及治疗方法 Download PDFInfo
- Publication number
- CN111936130A CN111936130A CN201980024658.7A CN201980024658A CN111936130A CN 111936130 A CN111936130 A CN 111936130A CN 201980024658 A CN201980024658 A CN 201980024658A CN 111936130 A CN111936130 A CN 111936130A
- Authority
- CN
- China
- Prior art keywords
- formulation
- strontium
- msm
- acid
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940016409 methylsulfonylmethane Drugs 0.000 title claims abstract description 92
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 229910052712 strontium Inorganic materials 0.000 title claims abstract description 54
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 22
- 239000012049 topical pharmaceutical composition Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 91
- 238000009472 formulation Methods 0.000 claims abstract description 87
- 230000007794 irritation Effects 0.000 claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 230000000699 topical effect Effects 0.000 claims abstract description 9
- 229940013553 strontium chloride Drugs 0.000 claims description 29
- 229910001631 strontium chloride Inorganic materials 0.000 claims description 29
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims description 29
- 206010015150 Erythema Diseases 0.000 claims description 28
- BDJRBEYXGGNYIS-UHFFFAOYSA-N azelaic acid group Chemical group C(CCCCCCCC(=O)O)(=O)O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 14
- 231100000321 erythema Toxicity 0.000 claims description 14
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 10
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 9
- 239000008406 cosmetic ingredient Substances 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 8
- 150000001280 alpha hydroxy acids Chemical group 0.000 claims description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 7
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- 150000004716 alpha keto acids Chemical class 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 229960003471 retinol Drugs 0.000 claims description 5
- 235000020944 retinol Nutrition 0.000 claims description 5
- 239000011607 retinol Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 229960000271 arbutin Drugs 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229940047908 strontium chloride hexahydrate Drugs 0.000 claims description 3
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 claims description 3
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 206010039792 Seborrhoea Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- -1 pyruvic acid) Chemical class 0.000 description 7
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002085 irritant Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 3
- 239000002561 chemical irritant Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 229940025703 topical product Drugs 0.000 description 3
- 206010006784 Burning sensation Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940006465 strontium cation Drugs 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
包含锶和甲基磺酰基甲烷(MSM)的局部化妆品或药物制剂减少了可能由皮肤处理组合物，尤其是低pH值皮肤处理引起的刺激。锶和甲基磺酰基甲烷可以与皮肤病学可接受的载体一起作为单独的制剂提供，或者可以在皮肤治疗制剂中与其他活性成分一起提供。
Description
技术领域
本公开总体上涉及包含锶和甲基磺酰基甲烷(MSM)的局部制剂和治疗方法。
背景技术
通常在使用低pH值的情况下，在局部化妆品和药品中使用高浓度的活性成分会产生所需的结果，这可能会引起副作用，例如刺激——包括刺痛、灼热、瘙痒、浮肿、其他不适感、发红等。
发明内容
在一方面，本发明是局部化妆品或药物制剂，其包含：锶、甲基磺酰基甲烷(MSM)和皮肤病学可接受的载体。
在另一方面，本发明是美容治疗的方法，其包括局部施用包含锶、 MSM和皮肤病学可接受的载体的局部制剂。
仍在另一方面，本发明是一种降低局部化妆品或药物制剂或其他化学刺激物对皮肤的刺激作用的方法，所述化妆品或药物制剂中包含锶和MSM。
附图说明
被视为本发明的主题在说明书的结论部分中特别指出并明确要求保护。然而，当结合附图阅读参考以下详细说明时，可以最好地理解本发明的组织和操作方法及其目的，特征和优点。
图1描绘了来自实施例I的比较临床数据，其显示了根据本发明的制剂对皮肤发红度(Δa*)的影响；
图2描绘了来自实施例I的比较临床数据，其显示了根据本发明的制剂对总体皮肤颜色(ΔE*)的影响；
图3描绘了来自实施例I的比较临床数据，其显示了根据本发明的制剂对皮肤刺激水平的影响；
图4示出了表1中所示数据的比较；
图5示出了表l中所示数据的从基线提高的比较；
图6描绘了来自实施例II的比较临床数据，其显示了根据本发明的制剂对皮肤发红度(Δa*)的影响；
图7描绘了来自实施例II的比较临床数据，其显示了根据本发明的制剂对总体皮肤颜色(ΔE*)的影响；
图8描述了来自实施例II的比较临床数据，其显示了根据本发明的制剂对皮肤刺激水平的影响；
图9示出了表2中所示数据的比较；和
图10示出了表2中所示数据的从基线提高的比较。
应当理解，为了图示的简单和清楚起见，图中所示的元件未必按比例绘制。例如，为了清楚起见，一些元件的尺寸可能相对于其他元件被放大。此外，在认为适当的情况下，可以在附图当中重复附图标记以指示对应或相似的元件。
具体实施方式
在下面的详细描述中，阐述了许多具体细节以便提供对本发明的透彻理解。然而，本领域技术人员将理解，可以在没有这些具体细节的情况下实践本发明。在其他情况下，未详细描述公知的方法、步骤和成分，以免模糊本发明。
本发明的实施方案涉及包含锶和甲基磺酰基甲烷(MSM)的制剂。锶和甲基磺酰基甲烷(MSM)的组合在本申请中可以称为“所述组合”。
本发明的其他实施方案涉及治疗或预防刺痛、瘙痒、灼热、红斑和其他感觉，及其发展的方法，它们与皮肤刺激性产品、化学物质、过程和刺激或类似感觉的其他原因有关、与温度变化有关、与灼伤或 pH值变化有关，其中所述方法包括施用包含锶和甲基磺酰基甲烷 (MSM)的制剂。
本发明涉及令人惊讶的发现，即在局部产品制剂中锶与甲基磺酰基甲烷(MSM)的组合可用于减少与局部施用的皮肤刺激物有关的刺激和红斑的发展、发生率和严重性，包括皮肤护理产品各种成分引起的刺激和神经性炎症。
锶与甲基磺酰基甲烷(MSM)的这种作用是协同作用。协同作用的特征在于两种材料的组合具有比每种材料的效果的简单总和更强的效果。在下面的实施例部分以及表1和2中对此进行了进一步说明。
协同作用还使得能够使用少量的锶和MSM，它们本身没有效果或效果非常小。
本发明通过向化妆品配方中添加锶和MSM使得能够在化妆品中使用高浓度的活性化妆品成分，通常具有低pH值，而没有由于化学刺激物或低pH值而引起的典型刺激和副作用(发红等)。
锶和MSM的组合可以用于包含活性化妆品成分的制剂和/或产品中，或在局部化妆品使用之前或之后使用，或在对皮肤进行治疗之前或之后使用(例如，激光治疗或其他治疗)或日晒后或灼伤后使用。当所述组合不是产品的一部分，并且在产品或治疗或日晒之前或之后使用时，应在时间上紧挨着使用所述组合，以达到减少刺激和红斑的期望效果。
本发明使得治疗皮肤的产品更有效，而没有典型的副作用：发红、发痒、灼热、刺痛等。产品的有效性得以提高，因为如果没有副作用或副作用较轻，受试者更可能遵医嘱来使用产品。另外，如果顾客/患者没有痛苦或不舒服，则进行/实施治疗的美容师/医生更有可能使产品保持更长的时间。例如，如果刺激性较小，则可以在处理区域上保留较长时间的化学剥离，从而获得呈现在产品中的全部功效。另外，由于消除或减少了刺激和发红的副作用，因此使受试者或从业者能够增加活性成分的量。
除了减少副作用外，添加锶和MSM不会损害或有损活性成分的有效性。
在一些实施方案中，所述组合可用于减轻与皮肤疾病例如特应性皮炎、湿疹、皮脂溢、酒渣鼻和牛皮癣相关的刺激和红斑。
在一些实施方案中，由于诸如“冬季瘙痒”的环境条件，该组合可以用于治疗干燥的皮肤。
在一些实施方案中，该组合用于治疗痤疮的产品中。
在一些实施方案中，该组合用于抗衰老产品中。
在一些实施方案中，锶和MSM可以在分开的产品中，并且一个接一个地应用，以实现减少刺激和红斑的期望效果。在一些实施例中，应用锶，然后立即应用MSM。在一些实施例中，应用MSM，然后立即应用锶。
在一些实施方案中，制剂还包含一种或多种另外的活性化妆品成分。
在一些实施方案中，另外的活性化妆品成分是α羟基酸(AHA) (包括乙醇酸、乳酸、扁桃酸、酒石酸、苹果酸和柠檬酸)、β羟基酸 (BHA)(包括水杨酸和柠檬酸)、视黄醇，α-酮酸(如丙酮酸)、二元羧酸(如壬二酸)、熊果苷(如α和β熊果苷)或维生素C。
在一个实施方案中，活性化妆品成分是壬二酸。
在一个实施方案中，活性化妆品成分是乙醇酸。
在一些实施方案中，本发明涉及局部产品中锶和MSM的组合，其对皮肤的美容治疗有效，并在治疗期间支持皮肤的舒缓和镇静，和皮肤的整体镇静，以及为皮肤提供美容效果，例如改善皮肤外观。当局部应用于皮肤时，该组合改善皮肤外观。
试验表明，当将锶和MSM的组合局部应用到皮肤上时，可以立即有效地防止刺痛、瘙痒、灼热的感觉、红斑和与皮肤刺激性产品、温度变化、灼伤、pH值变化、化学刺激物等有关的其他感觉，例如高浓度的AHA或BHA剥皮产品或含有视黄醇或α-酮酸(如丙酮酸)或二元羧酸(如壬二酸)的产品，或例如剃须后将海水应用于皮肤上。
含有锶和MSM的组合的制剂可有效地防止与产品相关的刺激的发展和抑制刺激，所述产品含有能够引起刺激的组分。
在一些实施方案中，当锶和甲基磺酰基甲烷(MSM)的组合局部应用到皮肤上时，其立即，有效且长时间防止刺痛、瘙痒、灼热的感觉、红斑和与皮肤刺激性化学物质和产品相关的其他感觉以及其他类型的神经性炎症。
所述组合还有效治疗由化学物质、温度变化、灼伤等以及低pH引起的感觉和神经性炎症，例如在AHA和BHA(α/β-羟基酸)剥皮产品、视黄醇和α-酮酸(例如丙酮酸)和二元羧酸(例如壬二酸)以及其他类型的化学剥皮产品和其他类型的会引起局部刺激的药品和化妆品中。与单独使用锶和MSM相比，它们的结合显著延长了抗刺激作用的持续时间。抗刺激作用是即时的和实时的，在应用组合物的时间和开始产生作用的时间之间无需等待。
在一些实施方案中，制剂中元素锶的浓度在0.1至10％w/w的范围内。在一些实施方案中，制剂中锶的浓度在2-8％w/w的范围内。在一些实施方案中，制剂中锶的浓度在2-4％w/w的范围内。在一些实施方案中，制剂中锶的浓度在4-6％w/w的范围内。在一些实施方案中，制剂中锶的浓度在6-8％w/w的范围内。在一些实施方案中，制剂中锶的浓度在5-7％w/w的范围内。在一些实施方案中，制剂中锶的浓度在 2-5％w/w的范围内。在一些实施方案中，制剂中锶的浓度在7-10％w/w 的范围内。在一些实施方案中，制剂中锶的浓度在8-10％w/w的范围内。在一些实施方案中，制剂中锶的浓度在0.1-2％w/w的范围内。在一些实施方案中，制剂中锶的浓度在0.1-15％w/w的范围内。在一些实施方案中，制剂中锶的浓度在10-15％w/w的范围内。
在一些实施方案中，制剂中锶的浓度在0.1至10％w/w的范围内。
在一些实施方案中，制剂中锶的浓度在2-8％w/w的范围内。
在一些实施方案中，制剂中MSM的浓度在0.1至20％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在5-10％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在5-7％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在7-10％w/w的范围内。在一些实施方案中，MSM的浓度在制剂中为6-8％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在6-9％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在0.1-5％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在10-20％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在10-15％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在15-20％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在0.1-3％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在3-5％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在0.1至40％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在20-40％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在20-30％w/w的范围内。在一些实施方案中，制剂中MSM的浓度在 30-40％w/w的范围内。
在一些实施方案中，制剂中MSM的浓度在0.1至20％w/w的范围内。
在一些实施方案中，制剂中MSM的浓度在5-10％w/w的范围内。
化妆品活性成分的浓度越高，推荐锶和MSM的组合浓度越高。
在一些实施方式中，锶阳离子的抗衡阴离子是卤素。
在一些实施方案中，卤素是氟化物(F-)，氯化物(C1-)，溴化物(Br-)或碘化物(I-)。
在一些实施方案中，卤素是氯化物。
在一些实施方案中，抗衡阴离子是有机的，例如羧酸，烷氧基化物，氨基酸(特别是赖氨酸、精氨酸、组氨酸、鸟氨酸、天冬氨酸、谷氨酸、脯氨酸和半胱氨酸)，肽，饱和和不饱和有机酸以及饱和和不饱和脂肪酸。
在一些实施方案中，有机抗衡阴离子是乙酸盐、乳酸盐、乙醇酸盐、酒石酸盐、马来酸盐、苯甲酸盐、丙酸盐、水杨酸盐、抗坏血酸盐、甲酸盐、琥珀酸盐、亚叶酸盐、天冬氨酸盐、邻苯二甲酸盐、油酸盐、棕榈酸盐、硬脂酸盐、月桂烷基硫酸盐、羊毛脂酸盐、肉豆蔻酸盐、山嵛酸盐、酪蛋白酸盐、甜蜜素、泛酸盐、EDTA或其他聚氨基多羧酸盐、糖精、巯基乙酸盐、月桂酸盐、对羟基苯甲酸甲酯、对羟基苯甲酸丙酯、蓖麻油酸酯或山梨酸盐阴离子。
在一些实施方案中，锶为氯化锶、乙酸锶或硝酸锶的形式。
在一些实施方案中，锶为六水合氯化锶的形式。
在一些实施方案中，所述制剂还包含皮肤病学可接受的载体。如本文所用，“皮肤病学可接受的载体”是指与制剂中的活性物相容的适合于局部施用于角质组织的载体，其不会引起安全性或毒性问题。皮肤病学可接受的载体的实例是本领域众所周知的，并且可以占化妆品制剂的约0.1至99.1％。
在一些实施方案中，以能够向患者的皮肤组织施用的任何药物或美容制剂形式施用所述组合物。
在一些实施方案中，本发明的组合物或局部药物包含载体。根据本发明的实施方案，载体为软膏、乳膏、洗剂、油、溶液(在一些实施方案中为水溶液)、乳剂、凝胶、糊剂、奶、气雾剂、粉末或泡沫的形式。在一些实施方案中，载体是水基载体(例如凝胶、水包油乳剂或水包油乳膏、水溶液、泡沫、洗剂、喷雾剂)。
在一些实施方案中，将制剂以诸如面膜、剥皮产品、肥皂(液体或固体)、洗发剂、剃须膏、须后水、防晒霜、香水、除臭剂、抗衰老和抗皱、人工晒黑、化妆品和卸妆产品、婴儿用品的产品施用。
在一些实施方案中，所述制剂为局部口服制剂的形式。在一些实施方案中，所述制剂以诸如漱口水或锭剂的产品形式施用。如本文所用，用于局部施用的生理上可接受的载体包括以上定义的皮肤病学可接受的载体，以及适于在口腔中局部施用的载体。
所述制剂/产品的典型应用方式包括手指，物理施用器，例如刷子、棒、棉签、薄纸或布，或者通过应用或粘附已经含有所述制剂的制备好的敷抹器，例如布面膜。
在一些实施方案中，所述制剂可以进一步包含以下一种或多种：乳化剂、溶剂、表面活性剂、防腐剂、保湿剂、香料、染料/着色剂、粘度调节剂、润肤剂、粘合剂、吸收剂、缓冲剂、螯合剂、调理剂。
本发明的制剂均保留了局部用产品的主要活性，同时允许制剂的抗刺激性和抗红斑活性为患者带来益处。
实施例
实施例I-乙醇酸50％(pH 0.9)
向15名23至64岁之间(平均45岁)的志愿者施用了包含50％乙醇酸(pH 0.9)的剥皮化妆品。在处理区域上保持剥皮产品10分钟。应用产品前和应用产品后10分钟，评估红斑和刺激(瘙痒、刺痛和灼热)。
所述剥皮产品进一步包含以下氯化锶和MSM的组合之一：
-不添加氯化锶，不添加MSM；
-仅10％MSM；
-仅5％氯化锶(约等于2.75％的元素锶)；或
-5％氯化锶+10％MSM。
不同类型的肤色(Fitzpatrick)和状况(油性、普通等)参加了试验。
使用比色计设备评估红斑，该比色计设备使用CIE-L*a*b*坐标提供值。
使用0到10的标准视觉模拟量表(VAS)评估刺激性。
结果示于下表1中，其中Δa*是剥皮产品前和剥皮产品后10分钟测量的发红度之间的差异，和ΔE*是剥皮产品前和剥皮产品后10分钟测量的总体皮肤色调之间的差异。
表中的第一行是“基准”行，其中在没有锶和/或MSM的情况下施用美容剥皮产品。表中的最后三列比较了Δa*、ΔE*和刺激性与基线的变化。例如，对于第二行，其中施用了10％MSM的Δa*为5.62(参与的受试者的平均值)，如第4列中指出的比基准行的Δa*低6.53％。
表1
从表1的结果中可以清楚地看出该组合的协同作用。10％MSM本身的Δa*为5.62，与基准相比降低6.53％，5％氯化锶本身的Δa*为5.44，与基准相比降低9.57％，而10％MSM和5％氯化锶的组合的Δa*为3.47，与基准相比降低42.33％。该减少量大于它们各自减少量的总和，因此证明了协同作用。
组合的效果也在附图中示出并在下面描述。
图1描绘了来自实施例I的比较临床数据，其显示了根据本发明的制剂对皮肤发红度(Δa*)的影响。Δa*％代表与之前的颜色相比，应用剥皮产品之后皮肤发红度增加的百分比。该图显示了15名志愿者中每人的这一变化。可以看出，最上面的三个图线包括以下三个组合：不添加氯化锶和不添加MSM；仅10％MSM和仅5％氯化锶，显示发红度增加约30-35％，而5％氯化锶和10％MSM的组合显示平均仅增加约20％。
图2描绘了来自实施例I的比较临床数据，其显示了根据本发明的制剂对总体皮肤颜色(ΔE*)的影响。ΔE*表示剥皮产品前和剥皮产品后测量的总体皮肤色调之间的差异。该图显示了15名志愿者中每人的这一变化。可以看出，5％氯化锶和10％MSM组合的总体皮肤色调变化低于其他三种组合。
图3描绘了来自实施例I的比较临床数据，其显示了根据本发明的制剂对皮肤刺激水平的影响。该图显示了在应用剥皮产品后10分钟测量的15位志愿者中每人的刺激水平。可以看出，5％氯化锶和10％ MSM的组合的刺激水平低于其他三种组合的水平。
图4描绘了表1的第1-3列中所示数据的比较，并显示了与其他三种组合相比，5％氯化锶和10％MSM的组合的所有三个参数Δa*、ΔE*和刺激性的值更低。
图5描绘了表1第4-6列中所示数据的从基线(不添加氯化锶和不添加MSM)提高的比较，并显示了与其他两种组合相比，5％氯化锶和10％MSM的组合的所有三个参数Δa*、ΔE*和刺激性与基线相比更高的降低百分比。
实施例II-壬二酸25％(pH 3.5)
向15名23至64岁之间(平均45岁)的志愿者施用了含有25％壬二酸(pH 3.5)的化妆品。应用产品前和应用产品后10分钟，评估红斑和刺激(瘙痒、刺痛和灼热)。
该产品进一步包含氯化锶和MSM的以下组合之一：
-不添加氯化锶，不添加MSM；
-仅10％MSM；
-仅含5％氯化锶(约等于2.75％的元素锶)；或
-5％氯化锶+10％MSM。
不同类型的肤色(Fitzpatrick)和状况(油性、普通等)参加了试验。
使用比色计设备评估红斑，该比色计设备使用CIE-L*a*b*坐标提供值。
使用0到10的标准视觉模拟量表(VAS)评估刺激性。
结果示于下表2中，其中Δa*是在应用产品之前和在应用产品之后10分钟测量的发红度之间的差异，和ΔE*是在应用产品之前和应用产品之后10分钟测量的总体皮肤色调之间的差异。
表中的第一行是“基准”行，其中在没有锶和/或MSM的情况下施用化妆品。表中的最后三列比较了Δa*、ΔE*和刺激性与基线的变化。例如，对于第二行，其中施用了10％MSM的Δa*为4.35，如第4列指出的比基准行的Δa*低3.77％。
表2：
从表2的结果中可以清楚地看出该组合的协同作用。10％MSM本身的Δa*为4.35，与基准相比降低3.77％，5％锶本身的Δa*为4.12，与基准相比减少8.83％，而10％MSM和5％锶的组合的Δa*为2.6，与基准相比减少42.47％。该减少量大于它们各自减少量的总和，因此证明了协同作用。
在附图中还示出了组合的效果。
图6描绘了来自实施例II的比较临床数据，其显示了根据本发明的制剂对皮肤发红度(Δa*)的影响。Δa*％代表与之前的颜色相比，应用该产品之后皮肤发红度增加的百分比。该图显示了15名志愿者中每人的这一变化。可以看出，最上面的三个图线包括以下三个组合：不添加氯化锶和不添加MSM；仅10％MSM和仅5％氯化锶，显示发红度增加约20-25％，而5％氯化锶和10％MSM的组合显示仅增加约 10-15％。
图7描绘了来自实施例II的比较临床数据，其显示了根据本发明的制剂对总体皮肤颜色(ΔE*)的影响。ΔE*代表使用产品之前和之后测量的总体皮肤色调之间的差异。该图显示了15名志愿者中每人的这一变化。可以看出，5％氯化锶和10％MSM组合的总体皮肤色调变化低于其他三种组合。
图8描绘了来自实施例II的比较临床数据，其显示了根据本发明的制剂对皮肤刺激水平的影响。该图显示了在应用产品后10分钟测量的15位志愿者中每人的刺激水平。可以看出，5％氯化锶和10％MSM 的组合的刺激水平低于其他三种组合的水平。
图9描绘了表2的第1-3列中所示数据的比较，并显示了与其他三种组合相比，5％氯化锶和10％MSM的组合的所有三个参数Δa*、ΔE*和刺激性的值更低。
图10描绘了表2的第4-6列中所示的数据的从基线(不添加氯化锶和不添加MSM)提高的比较，并显示了与其他两种组合相比，5％氯化锶和10％MSM的组合的所有三个参数Δa*、ΔE*和刺激性与基线相比更高的降低百分比。
尽管本文已经图示和描述了本发明的某些特征，但是本领域普通技术人员现在将想到许多修改、替换、改变和等同物。因此，应理解，本申请权利要求书旨在涵盖落入本发明的真实精神内的所有此类修改和改变。
Claims (23)
1.一种局部化妆品制剂，包含：
锶；
甲基磺酰基甲烷；和
生理上可接受的载体。
2.权利要求1的制剂，其中所述制剂中锶的浓度在约0.1-10％w/w的范围内。
3.权利要求1或权利要求2的制剂，其中所述制剂中甲基磺酰基甲烷的浓度在约0.1至20％w/w的范围内。
4.权利要求1-3中任一项的制剂，其中所述锶为氯化锶、乙酸锶、硝酸锶或六水合氯化锶的形式。
5.权利要求1-4中任一项的制剂，还包含至少一种另外的活性化妆品成分。
6.权利要求5的制剂，其中所述至少一种另外的活性化妆品成分是α羟基酸(AHA)、β羟基酸(BHA)、视黄醇、α酮酸、二元羧酸、熊果苷或维生素C。
7.权利要求5的制剂，其中所述至少一种另外的活性成分是壬二酸。
8.权利要求5的制剂，其中所述至少一种另外的活性成分是乙醇酸。
9.权利要求1-8中任一项的制剂，其中所述制剂为软膏、乳膏、洗剂、油、溶液、乳剂、凝胶、糊剂、奶、气雾剂、粉末或泡沫的形式。
10.一种美容治疗方法，包括向受试者局部施用用于局部施用的包含锶、甲基磺酰基甲烷(MSM)和生理上可接受的载体的制剂。
11.权利要求10的方法，其中所述方法减少刺激和红斑以及刺激和红斑的发展。
12.权利要求10或11中任一项的方法，其中所述制剂中锶的浓度在约0.1-10％w/w的范围内。
13.权利要求10至12中任一项的方法，其中所述制剂中MSM的浓度在约0.1-20％w/w的范围内。
14.权利要求10-13中任一项的方法，其中所述锶为氯化锶、乙酸锶、硝酸锶或六水合氯化锶的形式。
15.权利要求10至14中任一项的方法，在所述制剂中还包含至少一种另外的活性化妆品成分。
16.权利要求10至15中任一项的方法，其中所述至少一种另外的活性成分是α羟基酸(AHA)、β羟基酸(BHA)、视黄醇、α酮酸、二元羧酸、熊果苷或维生素C。
17.权利要求15的方法，其中至少一种活性成分是壬二酸。
18.权利要求15的方法，其中至少一种活性成分是乙醇酸。
19.权利要求10至18中任一项的方法，其中所述制剂为软膏、乳膏、洗剂、油、溶液、乳剂、凝胶、糊剂、奶、气雾剂、粉末或泡沫的形式。
20.权利要求1-9中任一项的制剂，其适于美容用途。
21.权利要求1-9中任一项的制剂，其适合用作药物。
22.权利要求1-9中任一项的制剂，其适用于减轻与皮肤疾病相关的刺激和红斑。
23.根据权利要求22使用的制剂，其中所述皮肤疾病是特应性皮炎、湿疹、皮脂溢、酒渣鼻或牛皮癣。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862654540P | 2018-04-09 | 2018-04-09 | |
| US62/654,540 | 2018-04-09 | ||
| PCT/IL2019/050386 WO2019198067A1 (en) | 2018-04-09 | 2019-04-04 | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111936130A true CN111936130A (zh) | 2020-11-13 |
| CN111936130B CN111936130B (zh) | 2024-05-28 |
Family
ID=68164619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980024658.7A Active CN111936130B (zh) | 2018-04-09 | 2019-04-04 | 包含锶和甲基磺酰基甲烷（msm）的局部制剂及治疗方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11918666B2 (zh) |
| EP (1) | EP3781152B1 (zh) |
| JP (1) | JP2021521153A (zh) |
| KR (1) | KR20200141046A (zh) |
| CN (1) | CN111936130B (zh) |
| AU (1) | AU2019251448A1 (zh) |
| BR (1) | BR112020020541A2 (zh) |
| CA (1) | CA3095602A1 (zh) |
| EA (1) | EA202092077A1 (zh) |
| ES (1) | ES2958132T3 (zh) |
| GE (1) | GEP20227384B (zh) |
| HR (1) | HRP20231153T1 (zh) |
| HU (1) | HUE063711T2 (zh) |
| IL (1) | IL277913A (zh) |
| MX (1) | MX2020010747A (zh) |
| PL (1) | PL3781152T3 (zh) |
| SG (1) | SG11202009799QA (zh) |
| WO (1) | WO2019198067A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115444766A (zh) * | 2022-02-17 | 2022-12-09 | 中国科学院过程工程研究所 | 一种具有头皮滋养功效的双组分洗发水及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024516652A (ja) * | 2021-04-30 | 2024-04-16 | ヌーン エスセティック エム．アール リミテッド | 過酸化ベンゾイルおよびアゼライン酸を含む外用剤およびその使用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031727A1 (en) * | 1994-12-21 | 2003-02-13 | Cosmederm Technologies, Llc | Topical product formulations containing strontium for reducing skin irritation |
| US20070270358A1 (en) * | 2004-05-24 | 2007-11-22 | De Paoliambrosi Gianfranco | Cosmetic and/or Pharmaceutical Composition for the Treatment of the Rosacea |
| US20080038219A1 (en) * | 2006-08-07 | 2008-02-14 | Calgenex Corporation | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof |
| US20100183741A1 (en) * | 2007-06-11 | 2010-07-22 | Galderma Research & Development | Dermatological compositions comprising at least one retinoid compound, an anti-irritant compound and benzoyl peroxide |
| EP2269615B1 (en) * | 2003-05-30 | 2018-03-07 | Gianfranco De Paoli Ambrosi | Use of dimethyl sulphone in formulations for chemical peeling |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| CN1795003A (zh) * | 2003-03-27 | 2006-06-28 | 桑托索尔夫公司 | 基于锶化合物的抗炎组合物 |
| ATE420631T1 (de) * | 2003-05-30 | 2009-01-15 | Paoli Ambrosi Gianfranco De | Kosmetische und/oder pharmazeutische zubereitung enthaltend dimthylsulphone und einen sonnenfilter für die behandlung und die prävention von reizungen, entzündungen und hauterythema |
| KR20070051258A (ko) * | 2004-06-23 | 2007-05-17 | 호프만 로버트 에프 | 표적화되는 산화적 치료 제형의 화상 치료에서의 용도 |
-
2019
- 2019-04-04 PL PL19785230.4T patent/PL3781152T3/pl unknown
- 2019-04-04 CA CA3095602A patent/CA3095602A1/en active Pending
- 2019-04-04 WO PCT/IL2019/050386 patent/WO2019198067A1/en unknown
- 2019-04-04 EA EA202092077A patent/EA202092077A1/ru unknown
- 2019-04-04 SG SG11202009799QA patent/SG11202009799QA/en unknown
- 2019-04-04 HU HUE19785230A patent/HUE063711T2/hu unknown
- 2019-04-04 BR BR112020020541-9A patent/BR112020020541A2/pt unknown
- 2019-04-04 MX MX2020010747A patent/MX2020010747A/es unknown
- 2019-04-04 JP JP2020555348A patent/JP2021521153A/ja active Pending
- 2019-04-04 EP EP19785230.4A patent/EP3781152B1/en active Active
- 2019-04-04 CN CN201980024658.7A patent/CN111936130B/zh active Active
- 2019-04-04 GE GEAP201915466A patent/GEP20227384B/en unknown
- 2019-04-04 HR HRP20231153TT patent/HRP20231153T1/hr unknown
- 2019-04-04 AU AU2019251448A patent/AU2019251448A1/en active Pending
- 2019-04-04 KR KR1020207029150A patent/KR20200141046A/ko not_active Application Discontinuation
- 2019-04-04 ES ES19785230T patent/ES2958132T3/es active Active
-
2020
- 2020-10-09 IL IL277913A patent/IL277913A/en unknown
- 2020-10-09 US US17/067,259 patent/US11918666B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031727A1 (en) * | 1994-12-21 | 2003-02-13 | Cosmederm Technologies, Llc | Topical product formulations containing strontium for reducing skin irritation |
| EP2269615B1 (en) * | 2003-05-30 | 2018-03-07 | Gianfranco De Paoli Ambrosi | Use of dimethyl sulphone in formulations for chemical peeling |
| US20070270358A1 (en) * | 2004-05-24 | 2007-11-22 | De Paoliambrosi Gianfranco | Cosmetic and/or Pharmaceutical Composition for the Treatment of the Rosacea |
| US20080038219A1 (en) * | 2006-08-07 | 2008-02-14 | Calgenex Corporation | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof |
| US20100183741A1 (en) * | 2007-06-11 | 2010-07-22 | Galderma Research & Development | Dermatological compositions comprising at least one retinoid compound, an anti-irritant compound and benzoyl peroxide |
Non-Patent Citations (1)
| Title |
|---|
| G S HAHN: "Strontium is a potent and selective inhibitor of sensory irritation", vol. 25, no. 9, XP002225553, DOI: 10.1046/j.1524-4725.1999.99099.x * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115444766A (zh) * | 2022-02-17 | 2022-12-09 | 中国科学院过程工程研究所 | 一种具有头皮滋养功效的双组分洗发水及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019251448A1 (en) | 2020-11-26 |
| US20210100725A1 (en) | 2021-04-08 |
| US11918666B2 (en) | 2024-03-05 |
| HUE063711T2 (hu) | 2024-01-28 |
| ES2958132T3 (es) | 2024-02-02 |
| EP3781152A1 (en) | 2021-02-24 |
| WO2019198067A1 (en) | 2019-10-17 |
| HRP20231153T1 (hr) | 2024-01-05 |
| CN111936130B (zh) | 2024-05-28 |
| IL277913A (en) | 2020-11-30 |
| EA202092077A1 (ru) | 2021-04-19 |
| EP3781152A4 (en) | 2022-01-05 |
| JP2021521153A (ja) | 2021-08-26 |
| SG11202009799QA (en) | 2020-11-27 |
| GEP20227384B (en) | 2022-05-25 |
| KR20200141046A (ko) | 2020-12-17 |
| CA3095602A1 (en) | 2019-10-17 |
| EP3781152B1 (en) | 2023-07-19 |
| PL3781152T3 (pl) | 2024-03-04 |
| MX2020010747A (es) | 2021-01-29 |
| EP3781152C0 (en) | 2023-07-19 |
| BR112020020541A2 (pt) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5572318B2 (ja) | 局所投与用アルギニンヘテロマー | |
| WO2002100359A1 (fr) | Preparations capillaires et/ou pour le cuir chevelu | |
| US20060222689A1 (en) | Skin care compositions and methods | |
| Bellad et al. | Development ofcosmeceuticals | |
| CA2933367A1 (en) | Exfoliative hair retention-promoting formulation | |
| CN111936130B (zh) | 包含锶和甲基磺酰基甲烷（msm）的局部制剂及治疗方法 | |
| CA2525465A1 (en) | Topical composition for transdermal administration | |
| JP2005524651A (ja) | にきびの治療のための局所用ダプソン | |
| JP2017193506A (ja) | 皮膚化粧料 | |
| JPS6360910A (ja) | 皮膚外用剤 | |
| JP5933207B2 (ja) | 化粧品用皮膚刺激緩和剤、及び、化粧品組成物 | |
| EP1752132A2 (en) | Skin cosmetic compositions | |
| WO2015057110A2 (en) | Cosmetic for rapid skin regeneration | |
| JPH11269043A (ja) | 頭皮頭髪用化粧料 | |
| JPS6322510A (ja) | 皮膚外用剤 | |
| JPH11302133A (ja) | 頭皮頭髪用化粧料 | |
| JPH11263714A (ja) | 頭皮頭髪用化粧料 | |
| JPH10273424A (ja) | 頭髪用化粧料 | |
| JP2007016025A (ja) | 皮膚の局部組成物及び方法 | |
| CA3217338A1 (en) | Topical formulations comprising benzoyl peroxide and azelaic acid, and use thereof | |
| Bilovol et al. | Сosmetology: textbook for the 2nd-year dentistry students (English medium) | |
| JPH1077216A (ja) | 養毛化粧料 | |
| EP4288025A1 (en) | Composition and method of non-therapeutic exfoliation of the epidermis | |
| JPH11349449A (ja) | 頭皮頭髪用化粧料 | |
| JPH11322546A (ja) | 頭皮頭髪用化粧料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |